Overview

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Status:
Recruiting

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).

Phase:

Phase 3

Details

Lead Sponsor:

Xynomic Pharmaceuticals, Inc.

Treatments:

Abexinostat